Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SORD | Q00796 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631909 | 0.77 | FGFR1 (0.40) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL631972 | 0.74 | FGFR1 (0.40) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL25836668 | 0.71 | HTT (0.42) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL502375 | 0.68 | HTT (0.39) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16523107 | 0.67 | HTT (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL9734970 | 0.67 | HTT (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL7256301 | 0.66 | FGFR1 (0.38) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Hydrochloric Acid SCHEMBL31531698 | 0.66 | HTT (0.40) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL7510881 | 0.66 | FGFR1 (0.35) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL3163041 | 0.65 | TAAR1 (0.61) | TAAR1FGFR1FGFR2FGFR4FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | TAAR1 419/4885FGFR1 1207/4885FGFR2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.